Plain-English translation of NCT05065216 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a Phase 2/3 trial testing whether a medication called DM199 can help people recover better after an acute ischemic stroke. Half of the participants will receive DM199 and half will receive a placebo (an inactive treatment), given as one intravenous dose followed by several injections over three weeks. The trial aims to enroll about 728 participants and will monitor their progress for 90 days to see if this medication is safe and effective.
Acute ischemic stroke is a serious medical emergency where blood flow to the brain is blocked. Currently, treatment options are limited, and researchers are looking for new ways to help patients recover better. This trial is testing whether this medication could improve outcomes when given early, within the first 24 hours after stroke symptoms begin.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either DM199 or placebo. You will receive one intravenous dose immediately, followed by injections under the skin at 2 hours after your IV dose and then twice weekly for up to three weeks. You will need to return for study visits and assessments throughout the 90-day period to allow doctors to monitor your recovery, safety, and how well the treatment works.
AI-generated summary from trial data · Jul 22, 2026 · Not medical advice
United States